Repurposing Infectious Diseases Vaccines Against Cancer
- PMID: 34055652
- PMCID: PMC8155725
- DOI: 10.3389/fonc.2021.688755
Repurposing Infectious Diseases Vaccines Against Cancer
Abstract
Vaccines used to prevent infections have long been known to stimulate immune responses to cancer as illustrated by the approval of the Bacillus Calmette-Guérin (BCG) vaccine to treat bladder cancer since the 1970s. The recent approval of immunotherapies has rejuvenated this research area with reports of anti-tumor responses with existing infectious diseases vaccines used as such, either alone or in combination with immune checkpoint inhibitors. Here, we have reviewed and summarized research activities using approved vaccines to treat cancer. Data supporting a cancer therapeutic use was found for 16 vaccines. For 10 (BCG, diphtheria, tetanus, human papillomavirus, influenza, measles, pneumococcus, smallpox, typhoid and varicella-zoster), clinical trials have been conducted or are ongoing. Within the remaining 6, preclinical evidence supports further evaluation of the rotavirus, yellow fever and pertussis vaccine in carefully designed clinical trials. The mechanistic evidence for the cholera vaccine, combined with the observational data in colorectal cancer, is also supportive of clinical translation. There is limited data for the hepatitis B and mumps vaccine (without measles vaccine). Four findings are worth highlighting: the superiority of intravesical typhoid vaccine instillations over BCG in a preclinical bladder cancer model, which is now the subject of a phase I trial; the perioperative use of the influenza vaccine to limit and prevent the natural killer cell dysfunction induced by cancer surgery; objective responses following intratumoral injections of measles vaccine in cutaneous T-cell lymphoma; objective responses induced by human papillomavirus vaccine in cutaneous squamous cell carcinoma. All vaccines are intended to induce or improve an anti-tumor (immune) response. In addition to the biological and immunological mechanisms that vary between vaccines, the mode of administration and sequence with other (immuno-)therapies warrant more attention in future research.
Keywords: drug repurposing; immunotherapy; infectious diseases; oncology; preventive vaccines.
Copyright © 2021 Vandeborne, Pantziarka, Van Nuffel and Bouche.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Highlights into historical and current immune interventions for cancer.Int Immunopharmacol. 2023 Apr;117:109882. doi: 10.1016/j.intimp.2023.109882. Epub 2023 Feb 27. Int Immunopharmacol. 2023. PMID: 36848790 Free PMC article. Review.
-
Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.Clin Cancer Res. 2017 Feb 1;23(3):717-725. doi: 10.1158/1078-0432.CCR-16-1189. Epub 2016 Aug 12. Clin Cancer Res. 2017. PMID: 27521445 Clinical Trial.
-
The Effect of Maternal Immunisation During Pregnancy on Infant Vaccine Responses.EClinicalMedicine. 2019 Jul 26;13:21-30. doi: 10.1016/j.eclinm.2019.06.010. eCollection 2019 Aug. EClinicalMedicine. 2019. PMID: 31517260 Free PMC article.
-
Co-administration of live measles and yellow fever vaccines and inactivated pentavalent vaccines is associated with increased mortality compared with measles and yellow fever vaccines only. An observational study from Guinea-Bissau.Vaccine. 2014 Jan 23;32(5):598-605. doi: 10.1016/j.vaccine.2013.11.074. Epub 2013 Dec 8. Vaccine. 2014. PMID: 24325827
-
Anti-Infectious Human Vaccination in Historical Perspective.Int Rev Immunol. 2016 May 3;35(3):260-90. doi: 10.3109/08830185.2015.1082177. Epub 2015 Nov 25. Int Rev Immunol. 2016. PMID: 26606466 Review.
Cited by
-
CanVaxKB: a web-based cancer vaccine knowledgebase.NAR Cancer. 2024 Jan 9;6(1):zcad060. doi: 10.1093/narcan/zcad060. eCollection 2024 Mar. NAR Cancer. 2024. PMID: 38204924 Free PMC article.
-
Anti-cancer Virotherapy in Russia: Lessons from the Past, Current Challenges and Prospects for the Future.Curr Pharm Biotechnol. 2023;24(2):266-278. doi: 10.2174/1389201023666220516121813. Curr Pharm Biotechnol. 2023. PMID: 35578840 Review.
-
Therapeutic Vaccination in Head and Neck Squamous Cell Carcinoma-A Review.Vaccines (Basel). 2023 Mar 13;11(3):634. doi: 10.3390/vaccines11030634. Vaccines (Basel). 2023. PMID: 36992219 Free PMC article. Review.
-
Editorial: Fighting fire with fire: Using non-pathogenic viruses to control unrelated infections.Front Immunol. 2022 Oct 6;13:1046851. doi: 10.3389/fimmu.2022.1046851. eCollection 2022. Front Immunol. 2022. PMID: 36275648 Free PMC article. No abstract available.
-
Resolution of recalcitrant verruca following Moderna COVID-19 vaccination in a person with HIV.JAAD Case Rep. 2023 Jan;31:118-120. doi: 10.1016/j.jdcr.2022.11.007. Epub 2022 Nov 12. JAAD Case Rep. 2023. PMID: 36406337 Free PMC article. No abstract available.
References
-
- Conti M. Repurposing Infectious Pathogen Vaccines in Cancer Immunotherapy. In: Drug Repurposing. London, UK: IntechOpen; (2020). p. 116–24. 10.5772/intechopen.92780 - DOI
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources